Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

SUPN has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.83.

Supernus Pharmaceuticals Trading Up 1.9%

Shares of SUPN stock opened at $47.64 on Thursday. Supernus Pharmaceuticals has a 12-month low of $40.26 and a 12-month high of $59.68. The business’s fifty day simple moving average is $46.17 and its 200-day simple moving average is $48.93. The company has a market cap of $2.77 billion, a PE ratio of -24.81, a PEG ratio of 0.76 and a beta of 0.56.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter worth $1,434,000. Phocas Financial Corp. acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $4,042,000. Westover Capital Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $1,587,000. Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares during the last quarter. Finally, Elmind Capital LP acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $994,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.